C. Ellervik et al., Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study, LANCET, 358(9291), 2001, pp. 1405-1409
Citations number
29
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Background Although genotyping studies suggest that hereditary haemochromat
osis is one of the most common genetic disorders in white people, it is sti
ll thought of as an uncommon disease. Our aim was to test the hypothesis th
at hereditary haemochromatosis is a disease often overlooked in patients wi
th late-onset type 1 diabetes mellitus, a late manifestation of untreated i
ron overload.
Methods We did a retrospective study in which we genotyped for the C282Y an
d H63D mutations in the haemochromatosis gene in 716 unselected Danish pati
ents who developed type I diabetes mellitus after age 30 years and 9174 con
trols from the general Danish population. We also screened for hereditary h
aemochromatosis by assessment of transferrin saturation.
Findings More patients with diabetes (n=9, relative frequency 1.26%, 95% CI
0.58-2.37) than controls (23, 0.25%, 0.16-0.38) were homozygous for C282Y
(odds ratio 4.6, 2.0-10.1, p=0.0001). These patients had unrecognised signs
of haemochromatosis. Transferrin saturation and ferritin concentrations ra
nged from 57% to 102% and 17 mug/L to 8125 mug/L, respectively. Frequency o
f compound heterozygosity (C282Y/H63D) did not differ between patients with
diabetes (eight) and controls (131) (odds ratio 0.8, 95% CI 0.4-1.7). Posi
tive and negative predictive values of transferrin saturation greater than
50%, in identification of C282Y homozygosity, were 0.26 and 1.00, respectiv
ely. A saturation of less than 50% therefore excluded C282Y homozygosity, w
hereas a saturation of more than 50% suggested C282Y homozygosity.
Interpretation Measurement of transferrin saturation followed by genetic te
sting could prevent liver and heart problems and improve life expectancy in
patients with diabetes. Population screening before the onset of diabetes
might improve the outlook of patients even further, but will be less cost e
ffective.